LifeStance CTO Sold Shares Valued at $541,402
The executive offloaded 42,067 shares following a period of significant stock price appreciation.
Updated on Sept. 23, 2026 in Public Companies
Live Poll
Does an executive selling company stock make you lose trust in that company's future?
On September 2, 2026, LifeStance Health Group CTO Vukasin Paunovich sold 42,067 shares of common stock at a weighted average price of $12.87 per share. This transaction resulted in a total value of $541,402.
Why it matters
The sale follows a high-growth period for the provider of outpatient mental health services, where share prices outperformed the broader market. Tracking internal equity movements helps operators monitor executive sentiment regarding the company's valuation after a 134.5% one-year gain.
The transaction involved 42,067 shares at an average price of $12.87, with the remaining 205,379 shares held by the CTO representing 0.05% of the company's total outstanding shares. LifeStance Health Group, which employs 8,542 people, reported $1.6 billion in trailing twelve-month revenue.
The players
Vukasin Paunovich
The Chief Technology Officer of LifeStance Health Group.
LifeStance Health Group
A provider of outpatient mental health services employing 8,542 people.
The details
The shares were liquidated through open-market transactions, with individual sale prices spanning a tight range between $12.86 and $12.905. Following this reduction, the CTO's remaining equity stake in the health services firm holds an estimated market value of approximately $2.6 million.
Timeline
September 2, 2026: Vukasin Paunovich completed the sale of 42,067 common shares.
Market Landscape
LifeStance Health Group's stock performance has significantly outpaced the S&P 500 benchmark over the past year. This executive divestment occurs in the context of that marked outperformance relative to the broader market index.
Operators should monitor executive equity activity as a potential signal of internal outlook regarding recent valuation surges. While individual sales are common, significant shifts in leadership ownership percentages are worth noting in future regulatory disclosures.
The takeaway
Large discrepancies between individual stock performance and broad market indices often invite institutional scrutiny of insider activity. Operators should consider monitoring SEC Form 4 filings for their peers to calibrate expectations for long-term equity performance.
Further reading
For broader trends in executive equity management, see the Public Companies section.
Source note: This article includes information reported by The Motley Fool.
Live Poll
Does an executive selling company stock make you lose trust in that company's future?
